InMed’s CEO, Eric A. Adams, will be giving a company presentation at the Life Sciences Investor Forum.

September 18, 2025
2:00pm ET
Register free here to watch: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5073850/inmed-pharamaceuticals-inc-nasdaq-inm

Learn more about the Life Sciences Investor Forum.

The InMed management team will be available for 1×1 meetings at this investor forum. If you would like to request a meeting, you can schedule a meeting here.

A pre-recorded presentation from InMed will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of InMed’s management team will also be conducting one-on-one meetings with investors.

H.C. Wainwright 27th Annual Global Investment Conference
Presentation available: Beginning Friday, September 5, 2025, 7:00am ET
Format: Pre-recorded webcast

Link to podcast available starting September 5th, 7:00am ET: InMed’s company presentation at H.C. Wainwright 27th Global Investment Conference

The webcast will be available for 90 days

Visit conference website

InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, attending the 2025 Alzheimer’s Association International Conference, in Toronto, Canada.

Data on InMed’s Alzheimer’s disease drug candidate INM-901 was presented in a scientific poster entitled, “Therapeutic Potential of INM-901 in Mitigating Alzheimer’s Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study”.

View the poster here.

Event details here: https://aaic.alz.org/

InMed’s President and CEO, Eric A. Adams, will be attending the 2025 J.P. Morgan Healthcare Conference in San Francisco California.

Event details here: https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

InMed is proud to take part in the upcoming Fierce Biotech webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step.”

InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, will join a panel of experts to speak about recent breakthroughs in Alzheimer’s disease research and the effects of neuroinflammation in disease progression. Details are as follows:

Alzheimer’s Outlook – Neuroinflammation, the Next Step

Date: November 12, 2024
Time: 2:00pm ET
Now available on demand: https://www.fiercebiotech.com/premium/webinar/breakthroughs-alzheimers-research-and-drug-development

In this webinar, we’ll hear about:

• the latest research into the causes of Alzheimer’s disease
• the different therapeutic pathways being explored
• drugs in development and their pharmacological targets
• the pathophysiological effects of neuroinflammation in Alzheimer’s disease

If you are a neurodegenerative disease researcher or clinician or study brain health or are a caregiver for someone living with Alzheimer’s disease, join this webinar to learn what the future holds in Alzheimer’s disease therapeutic development.

Speakers for this event:

• Phyllis Ferrell, DrPH, MBA (Moderator), Chief Impact Officer at StartUp Health’s Alzheimer’s Moonshot
• David Morgan, PhD, Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University
• Marwan Sabbagh, MD, Moreno Family Chair for Alzheimer’s Research and Vice Chairman for Research and Professor of Neurology at the Barrow Neurological Institute in Phoenix Arizona
• Barry Greenberg, PhD, Associate Professor in the Department of Neurology and Director of Alzheimer’s Disease Translational Center at the Johns Hopkins University School of Medicine
• Eric Hsu, PhD, Senior Vice President of Preclinical Research and Development at InMed Pharmaceuticals

InMed’s President and CEO, Eric A. Adams, will be presenting at this year’s H.C. Wainwright Annual Global Investment Conference.

H.C. Wainwright 26th Annual Global Investment Conference
New York, NY
September 9-11, 2024

Visit conference website

InMed’s CEO, Eric A. Adams, and Senior VP of Preclinical Research and Development, Dr. Eric Hsu, will be attending the Alzheimer’s Association International Conference in Philadelphia, PA.

Dates: July 28 – August 1, 2024
Alzheimer’s Association International Conference Website

InMed’s CEO Eric A. Adams is presenting at Emerging Growth Conference 72 where he’ll give an update on the progress of the company’s pharmaceutical programs, including preclinical programs Alzheimer’s disease and age-related macular degeneration.

The Emerging Growth Conference 72 is June 12-13, 2024

Presentation details:
Date: June 13, 2024
Time: 1:45pm-2:15pm ET

Presentation video replay available here.

Conference website: https://emerginggrowth.com/emerging-growth-conference-72/

InMed’s CEO Eric A. Adams will be presenting at this year’s Benzinga Healthcare + Biotech Breakthroughs.

Date: Thursday, June 20th
Time: 11:00am ET

Watch presentation replay here.

About the Benzinga Healthcare & Biotech Breakthroughs conference: These speakers will share their experiences and the latest developments from their respective companies that contribute to improving healthcare delivery and patient outcomes. The conference aims to provide attendees with a detailed overview of cutting-edge technologies and processes that are setting new standards in healthcare. Topics of discussion will include the development of new medical treatments and improving biotech tools that aid in disease prevention and management.

InMed CEO Eric A. Adams will join Water Tower Research in this Fireside Chat.

Date: January 25, 2024
Time: 1:00pm ET

Interested parties can register for the event here. Replays of the webcast will also be available after the event.

In this fireside chat, CEO Eric A. Adams will provide an update on our pharmaceutical programs and upcoming milestones. This event is open access for all investors. Topics will include:

• An overview of InMed’s pharmaceutical pipeline in Alzheimer’s and Age-related Macular Degeneration (“AMD”)
• A discussion of upcoming 2024 milestones in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives
• An overview of cannabinoids and their possible role in the treatment of Alzheimer’s